CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

E3 ubiquitin ligases and their therapeutic potential in disease Management

Madhukar, Geet, Haque, Md Azizul, Khan, Shawez, Kim, Jong-Joo, Danishuddin·2025·Biochemical Pharmacology
DOI 10.1016/j.bcp.2025.116875
Open this paper in CoChat — free account

Abstract

Ubiquitination is a vital post-translational modification that regulates protein stability and various cellular processes through the addition of ubiquitin molecules. Central to this process are E3 ubiquitin ligases, which determine the specificity of ubiquitination by coordinating the attachment of ubiquitin to target proteins, influencing their degradation, localization, and activity. E3 ubiquitin ligases are involved in numerous cellular pathways, including DNA repair, cell proliferation, and immune responses. Dysregulation of E3 ubiquitin ligases is often associated with cancer, contributing to tumor progression and resistance to therapies. The development of targeted protein degraders, such as proteolysis-targeting chimeras (PROTACs), represents a significant advancement in drug discovery, leveraging the specificity of E3 ubiquitin ligases to selectively eliminate pathogenic proteins. However, challenges remain in translating this knowledge into effective therapies, including issues related to tissue-specific targeting and off-target effects. The limitations also include a limited understanding of ligase-substrate interactions that includes both the identification of novel E3 ligases and their substrates, as well as understanding the dynamic, context-dependent nature of these interactions, which can vary across tissue types or disease states This review emphasizes the therapeutic potential of E3 ubiquitin ligases, exploring their diverse roles in disease, their contribut…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2025.116875

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Research works printed but not linked: 304

  1. Sampson, 2023, The roles of E3 ubiquitin ligases in cancer progression and targeted therapy, Clin Transl Med, 13, 10.1002/ctm2.1204 · DOI
  2. Varshavsky, 2006, The early history of the ubiquitin field, Protein Sci., 15, 10.1110/ps.052012306 · DOI
  3. Barford, 2020, Structural interconversions of the anaphase-promoting complex/cyclosome (APC/C) regulate cell cycle transitions, Curr Opin Struct Biol, 61, 10.1016/j.sbi.2019.11.010 · DOI
  4. Zhang, 2020, Cullin RING Ligase 5 (CRL-5): Neddylation Activation and Biological Functions, Advances in Experimental Medicine and Biology
  5. Varshavsky, 2006, The early history of the ubiquitin field, Protein Sci., 15, 647, 10.1110/ps.052012306 · DOI
  6. Neefjes, 2004, The 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, Ned Tijdschr Geneeskd, 148, 2579
  7. S. Zhang, Y. Sun, Cullin RING Ligase 5 (CRL-5): Neddylation Activation and Biological Functions, in: 2020: pp. 261–283. https://doi.org/10.1007/978-981-15-1025-0_16. · DOI
  8. Barford, 2020, Structural interconversions of the anaphase-promoting complex/cyclosome (APC/C) regulate cell cycle transitions, Curr Opin Struct Biol, 61, 86, 10.1016/j.sbi.2019.11.010 · DOI
  9. Marsh, 2020, Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer, Cancers (Basel), 12, 10.3390/cancers12113462 · DOI
  10. Chen, 2022, Monoubiquitination in Homeostasis and Cancer, Int J Mol Sci, 23, 5925, 10.3390/ijms23115925 · DOI
  11. Liu, 2022, An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine, 3, 10.1186/s43556-022-00112-0 · DOI
  12. Schulman, 2009, Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways, Nat Rev Mol Cell Biol, 10, 10.1038/nrm2673 · DOI
  13. Groen, 2015, UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration, Trends Mol Med, 21, 10.1016/j.molmed.2015.08.003 · DOI · Paper page
  14. Xu, 2010, The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma, Blood, 115, 10.1182/blood-2009-07-231191 · DOI
  15. Olsen, 2013, Structure of a Ubiquitin E1-E2 Complex: Insights to E1-E2 Thioester Transfer, Mol Cell, 49, 10.1016/j.molcel.2013.01.013 · DOI
  16. Stewart, 2016, E2 enzymes: More than just middle men, Cell Res, 26, 10.1038/cr.2016.35 · DOI
  17. Taylor, 2024, Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes, Commun Biol 7, 10.1038/s42003-024-06803-4 · DOI
  18. Qi, 2022, Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis, Mol Cancer, 21, 10.1186/s12943-022-01538-4 · DOI
  19. Wu, 2017, Structural analysis of recombinant human ubiquitin-conjugating enzyme UbcH5c, Acta Pharm Sin B, 7, 10.1016/j.apsb.2016.12.008 · DOI
  20. Blaquiere, 2020, Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases, J Med Chem, 63, 7957, 10.1021/acs.jmedchem.9b01451 · DOI
  21. H.C. Nguyen, W. Wang, Y. Xiong, Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction, in: 2017: pp. 323–347. https://doi.org/10.1007/978-3-319-46503-6_12. · DOI
  22. Zheng, 2016, Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins, Int J Biochem Cell Biol, 73, 99, 10.1016/j.biocel.2016.02.005 · DOI
  23. D’Amico, 2021, Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class, Chembiochem, 22
  24. Michaelides, 2023, E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology, J Med Chem, 66, 3173, 10.1021/acs.jmedchem.2c01882 · DOI
  25. Yang, 2021, E3 ubiquitin ligases: styles, structures and functions, Molecular Biomedicine 2, 23, 10.1186/s43556-021-00043-2 · DOI · Paper page
  26. Ichikawa, 2022, The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron, Nature, 610, 775, 10.1038/s41586-022-05333-5 · DOI · Paper page
  27. Lucas, 2017, Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies, Curr Opin Struct Biol, 44, 101, 10.1016/j.sbi.2016.12.015 · DOI
  28. Blaquiere, 2020, Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases, J Med Chem, 63, 10.1021/acs.jmedchem.9b01451 · DOI
  29. Spano, 2024, Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy, Cells, 13
  30. Lucas, 2017, Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies, Curr Opin Struct Biol, 44, 10.1016/j.sbi.2016.12.015 · DOI
  31. Madiraju, 2022, K63 ubiquitination in immune signaling, Trends Immunol, 43, 10.1016/j.it.2021.12.005 · DOI
  32. Nakasone, 2022, Structure of UBE2K–Ub/E3/polyUb reveals mechanisms of K48-linked Ub chain extension, Nat Chem Biol, 18, 10.1038/s41589-021-00952-x · DOI
  33. Ohtake, 2018, K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains, Proc Natl Acad Sci U S A, 115, 10.1073/pnas.1716673115 · DOI
  34. Ohtake, 2016, The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling, Mol Cell, 64, 10.1016/j.molcel.2016.09.014 · DOI
  35. Tracz, 2021, Beyond K48 and K63: non-canonical protein ubiquitination, Cell Mol Biol Lett, 26, 10.1186/s11658-020-00245-6 · DOI
  36. Xu, 2009, Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation, Cell, 137, 10.1016/j.cell.2009.01.041 · DOI
  37. van Huizen, 2020, The Role of Atypical Ubiquitin Chains in the Regulation of the Antiviral Innate Immune Response, Front Cell Dev Biol, 7, 10.3389/fcell.2019.00392 · DOI
  38. Gao, 2023, The mechanism of linear ubiquitination in regulating cell death and correlative diseases, Cell Death Dis, 14, 659, 10.1038/s41419-023-06183-3 · DOI
  39. Dittmar, 2020, Linear Ubiquitin Chains: Cellular Functions and Strategies for Detection and Quantification, Front Chem, 7, 10.3389/fchem.2019.00915 · DOI
  40. Zhang, 2021, Hypoxia regulates overall mRNA homeostasis by inducing Met1-linked linear ubiquitination of AGO2 in cancer cells, Nat Commun, 12
  41. Spagnol, 2016, Structural Studies of the Nedd4 WW Domains and Their Selectivity for the Connexin43 (Cx43) Carboxyl Terminus, J. Biol. Chem., 291, 7637, 10.1074/jbc.M115.701417 · DOI
  42. Kramer IJM, Signaling through the Insulin Receptor: Phosphoinositide 3-Kinases and AKT , in: Signal Transduct, Third, Elsevier Inc., 2016: pp. 849–886. · DOI
  43. Zhao, 2022, Targeted protein degradation: mechanisms, strategies and application, Signal Transduct Target Ther, 7, 113, 10.1038/s41392-022-00966-4 · DOI
  44. Békés, 2022, PROTAC targeted protein degraders: the past is prologue, Nat Rev Drug Discov, 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  45. Sun, 2023, The Role of HECT E3 Ubiquitin Ligases in Colorectal Cancer, Biomedicines, 11, 478, 10.3390/biomedicines11020478 · DOI
  46. D’Amico, 2021, Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class, Chembiochem, 22, 2011, 10.1002/cbic.202000787 · DOI
  47. Metzger, 2012, HECT and RING finger families of E3 ubiquitin ligases at a glance, J Cell Sci, 125, 10.1242/jcs.091777 · DOI
  48. Spano, 2023, Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy, Cells, 13, 29, 10.3390/cells13010029 · DOI
  49. Yang, 2021, E3 ubiquitin ligases: styles, structures and functions, Molecular Biomedicine, 2, 10.1186/s43556-021-00043-2 · DOI · Paper page
  50. Jeong, 2023, Tripartite Motif-Containing Protein 32 (TRIM32): What Does It Do for Skeletal Muscle?, Cells, 12, 10.3390/cells12162104 · DOI
  51. Traweek, 2022, Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma, Front Oncol, 12, 10.3389/fonc.2022.1006959 · DOI
  52. Munir, 2010, TRIM proteins: Another class of viral victims, Sci Signal, 3, 10.1126/scisignal.3118jc2 · DOI
  53. Nag, 2014, Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?, Curr Med Chem, 21, 10.2174/09298673113206660325 · DOI
  54. Metzger, 2014, RING-type E3 ligases: Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination, Biochim Biophys Acta Mol Cell Res, 1843, 10.1016/j.bbamcr.2013.05.026 · DOI
  55. Budhidarmo, 2014, The ubiquitin-associated domain of cellular inhibitor of apoptosis proteins facilitates ubiquitylation, J. Biol. Chem., 289, 10.1074/jbc.M113.545475 · DOI
  56. D.-V. Rusnac, N. Zheng, Structural Biology of CRL Ubiquitin Ligases, in: 2020: pp. 9–31. https://doi.org/10.1007/978-981-15-1025-0_2. · DOI
  57. K. Wang, R.J. Deshaies, X. Liu, Assembly and Regulation of CRL Ubiquitin Ligases, in: 2020: pp. 33–46. https://doi.org/10.1007/978-981-15-1025-0_3. · DOI
  58. Wang, 2020, Assembly and Regulation of CRL Ubiquitin Ligases, Advances in Experimental Medicine and Biology, 10.1007/978-981-15-7086-5 · DOI
  59. Rusnac, 2020, Structural Biology of CRL Ubiquitin Ligases, Advances in Experimental Medicine and Biology, 10.1007/978-981-15-1025-0_2 · DOI
  60. Nguyen, 2020, The Biology of F-box Proteins: The SCF Family of E3 Ubiquitin Ligases, Advances in Experimental Medicine and Biology, 10.1007/978-981-15-1025-0_8 · DOI
  61. William, 2024, SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies, Front, Oncol, 14
  62. Zheng, 2016, Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins, Int. J. Biochem. Cell Biol., 73, 10.1016/j.biocel.2016.02.005 · DOI
  63. Schrock, 2020, APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis, Semin Cancer Biol, 67, 10.1016/j.semcancer.2020.03.001 · DOI
  64. Yamano, 2019, APC/C: current understanding and future perspectives, F1000Res, 8, 10.12688/f1000research.18582.1 · DOI
  65. Liu, 2012, GPS-ARM: Computational analysis of the APC/C recognition motif by predicting D-boxes and KEN-boxes, PLoS One, 7
  66. Pfleger, 2000, The KEN box: An APC recognition signal distinct from the D box targeted by Cdh1, Genes Dev, 14, 10.1101/gad.14.6.655 · DOI
  67. Hagting, 2002, Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1, J. Cell Biol., 157, 10.1083/jcb.200111001 · DOI
  68. Greil, 2022, The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy, Front Genet, 13, 10.3389/fgene.2022.941565 · DOI
  69. Kalb, 2014, BRCA1 is a histone-H2A-specific ubiquitin ligase, Cell Rep, 8, 10.1016/j.celrep.2014.07.025 · DOI
  70. Witus, 2021, The BRCA1/BARD1 ubiquitin ligase and its substrates, Biochem. J, 478
  71. Mallery, 2002, Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains, EMBO J., 21, 10.1093/emboj/cdf691 · DOI
  72. Wang, 2020, HECT E3 ubiquitin ligases – emerging insights into their biological roles and disease relevance, J Cell Sci, 133
  73. Qian, 2020, Structure and function of HECT E3 ubiquitin ligases and their role in oxidative stress, J Transl Int Med, 8, 71, 10.2478/jtim-2020-0012 · DOI
  74. Haouari, 2022, The roles of NEDD4 subfamily of HECT E3 ubiquitin ligases in neurodevelopment and neurodegeneration, Int J Mol Sci, 23, 10.3390/ijms23073882 · DOI
  75. Tanahashi, 2020, The C2 domain of the ubiquitin ligase Rsp5 is required for ubiquitination of the endocytic protein Rvs167 upon change of nitrogen source, FEMS Yeast Res, 20, 10.1093/femsyr/foaa058 · DOI
  76. Scott, 2020, Molecular analysis of membrane targeting by the C2 domain of the E3 ubiquitin ligase smurf1, Biomolecules, 10, 10.3390/biom10020229 · DOI
  77. Dunn, 2004, The C2 domain of the Rsp5 ubiquitin ligase binds membrane phosphoinositides and directs ubiquitination of endosomal cargo, J. Cell Biol., 165, 10.1083/jcb.200309026 · DOI
  78. Madhukar, 2020, In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas, J Biomol Struct Dyn
  79. Jayaprakash, 2022, Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer, Int J Mol Sci, 23, 12380, 10.3390/ijms232012380 · DOI
  80. Sala-Gaston, 2020, HERC Ubiquitin Ligases in Cancer, Cancers (Basel), 12, 1653, 10.3390/cancers12061653 · DOI
  81. Yoo, 2011, Frameshift mutations of ubiquitination-related genes HERC2, HERC3, TRIP12, UBE2Q1 and UBE4B in gastric and colorectal carcinomas with microsatellite instability, Pathology, 43, 753, 10.1097/PAT.0b013e32834c7e78 · DOI
  82. Sánchez-Tena, 2016, Functional and pathological relevance of HERC family proteins: a decade later, Cell. Mol. Life Sci., 73, 1955, 10.1007/s00018-016-2139-8 · DOI
  83. Pérez-Villegas, 2022, The HERC proteins and the nervous system, Semin Cell Dev Biol, 132, 5, 10.1016/j.semcdb.2021.11.017 · DOI
  84. Elpidorou, 2021, Novel loss-of-function mutation in HERC2 is associated with severe developmental delay and paediatric lethality, J Med Genet, 58, 334, 10.1136/jmedgenet-2020-106873 · DOI
  85. Ali, 2022, The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation, J Clin Med, 11, 324, 10.3390/jcm11020324 · DOI
  86. K.M. Nguyen, L. Busino, The Biology of F-box Proteins: The SCF Family of E3 Ubiquitin Ligases, in: 2020: pp. 111–122. https://doi.org/10.1007/978-981-15-1025-0_8. · DOI
  87. Singh, 2021, Exploring the “Other” subfamily of HECT E3-ligases for therapeutic intervention, Pharmacol Ther, 224, 10.1016/j.pharmthera.2021.107809 · DOI
  88. Wang, 2020, NEDD4 E3 ligase: Functions and mechanism in human cancer, Semin Cancer Biol, 67, 92, 10.1016/j.semcancer.2020.03.006 · DOI
  89. Uchida, 2016, RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer, Curr Cancer Drug Targets, 16, 157, 10.2174/1568009616666151112122801 · DOI
  90. Cotton, 2020, Chain reactions: molecular mechanisms of RBR ubiquitin ligases, Biochem Soc Trans, 48, 1737, 10.1042/BST20200237 · DOI
  91. Smit, 2014, RBR E3-ligases at work, EMBO Rep, 15, 142, 10.1002/embr.201338166 · DOI
  92. Marín, 2002, Comparative genomics of the RBR family, including the Parkinson’s disease-related gene parkin and the genes of the ariadne subfamily, Mol Biol Evol, 19, 10.1093/oxfordjournals.molbev.a004029 · DOI
  93. Jeong, 2023, Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases, Exp Mol Med, 55, 10.1038/s12276-023-01087-w · DOI
  94. Marín, 2004, Parkin and relatives: The RBR family of ubiquitin ligases, Physiol Genomics, 17, 10.1152/physiolgenomics.00226.2003 · DOI
  95. Xu, 2020, PINK1-mediated mitophagy protects against hepatic ischemia/reperfusion injury by restraining NLRP3 inflammasome activation, Free Radic Biol Med, 160, 10.1016/j.freeradbiomed.2020.09.015 · DOI
  96. Riley, 2013, Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases, Nat Commun, 4, 10.1038/ncomms2982 · DOI
  97. Liu, 2018, Parkinson’s disease-associated protein Parkin: An unusual player in cancer, Cancer Commun, 38, 10.1186/s40880-018-0314-z · DOI
  98. Wu, 2023, Structural basis for ubiquitylation by HOIL-1, Front Mol Biosci, 9, 10.3389/fmolb.2022.1098144 · DOI
  99. Liu, 2019, RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC), Biomed. Pharmacother., 118, 10.1016/j.biopha.2019.109250 · DOI
  100. Cai, 2022, The RING finger protein family in health and disease, Signal Transduct Target Ther, 7
  101. Zhang, 2023, CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer, Drug Resist. Updat., 67, 10.1016/j.drup.2022.100912 · DOI
  102. Cheng, 2021, Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth, J Cell Mol Med, 25, 10.1111/jcmm.16674 · DOI
  103. Yang, 2023, RNF144A promotes antiviral responses by modulating STING ubiquitination, EMBO Rep, 24, 10.15252/embr.202357528 · DOI
  104. Dove, 2016, Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms, EMBO Rep, 17, 10.15252/embr.201642641 · DOI
  105. Lv, 2023, Long non-coding RNA SNHG4 enhances RNF14 mRNA stability to promote the progression of colorectal cancer by recruiting TAF15 protein, Apoptosis, 28, 10.1007/s10495-022-01781-6 · DOI
  106. Wu, 2013, Ring Finger Protein 14 is a new regulator of TCF/β-catenin-mediated transcription and colon cancer cell survival, EMBO Rep, 14, 10.1038/embor.2013.19 · DOI
  107. Chen, 2022, RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31, Cell Death Discov, 8, 10.1038/s41420-022-01126-x · DOI
  108. Wang, 2023, The unifying catalytic mechanism of the RING-between-RING E3 ubiquitin ligase family, Nat Commun, 14
  109. Guenette, 2022, Target and tissue selectivity of PROTAC degraders, Chem Soc Rev, 51, 5740, 10.1039/D2CS00200K · DOI · Paper page
  110. Goel, 2015, NEDD4-2 (NEDD4L): The ubiquitin ligase for multiple membrane proteins, Gene, 557, 10.1016/j.gene.2014.11.051 · DOI
  111. Jin, 2010, Genetic variations in the sodium balance-regulating genes ENaC, NEDD4L, NDFIP2 and USP2 influence blood pressure and hypertension, Kidney Blood Press Res, 33, 10.1159/000275706 · DOI
  112. Han, 2024, Aberrant expression of NEDD4L disrupts mitochondrial homeostasis by downregulating CaMKKβ in diabetic kidney disease, J Transl Med, 22, 1, 10.1186/s12967-024-05207-6 · DOI
  113. Niu, 2022, Associations of genetic variations in NEDD4L with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults, J Clin Hypertens, 24, 10.1111/jch.14566 · DOI
  114. Zhang, 2020, A variant in the NEDD4L gene associates with hypertension in chronic kidney disease in the southeastern Han Chinese population, Am J Hypertens, 33, 10.1093/ajh/hpaa015 · DOI
  115. Luo, 2009, A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension, Hypertension, 54, 10.1161/HYPERTENSIONAHA.109.135103 · DOI
  116. Zeng, 2020, Diminution of microRNA-98 alleviates renal fibrosis in diabetic nephropathy by elevating Nedd4L and inactivating TGF-β/Smad2/3 pathway, Cell Cycle, 19, 10.1080/15384101.2020.1838780 · DOI
  117. Henshall, 2017, Deletion of Nedd4-2 results in progressive kidney disease in mice, Cell Death Differ, 24, 10.1038/cdd.2017.137 · DOI
  118. Chen, 2023, Identification and study of regulatory axis that miRNA 224 5p targets NEDD4L gene in clear cell renal cell carcinoma, Cancer Research and Clinic, 35
  119. Wu, 2022, Ubiquitin ligase E3 HUWE1/MULE targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury, Cell Death Differ, 29, 10.1038/s41418-022-00957-6 · DOI
  120. Luo, 2024, CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma, Nat Commun, 15, 10594, 10.1038/s41467-024-54354-3 · DOI
  121. Peter, 2014, Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase, EMBO Mol Med, 6, 1525, 10.15252/emmm.201403927 · DOI
  122. Moser, 2019, Regulation of autoimmune disease by the E3 ubiquitin ligase Itch, Cell Immunol, 340, 10.1016/j.cellimm.2019.04.004 · DOI
  123. Liu, 2007, The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance, Semin Immunol, 19, 10.1016/j.smim.2007.02.003 · DOI
  124. Huang, 2010, K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling, Immunity, 33, 60, 10.1016/j.immuni.2010.07.002 · DOI
  125. Patel, 2021, Immune Dysregulation in Human ITCH Deficiency Successfully Treated with Hematopoietic Cell Transplantation, Journal of Allergy and Clinical Immunology, In Pract., 9
  126. P. t., c. m., m. e., f. n., m. k., d. n., g. c., h. s., w. e., d. m., b. n., f. j., h. j., a. d., m. j., o. p., s. k.,, 2019, Novel treatment of itch deficiency in very early-onset inflammatory bowel disease with hematopoietic stem cell transplantation, J Pediatr Gastroenterol Nutr, 69
  127. G. Melino, E. Gallagher, R.I. Aqeilan, R. Knight, A. Peschiaroli, M. Rossi, F. Scialpi, M. Malatesta, L. Zocchi, G. Browne, A. Ciechanover, F. Bernassola, Itch: a HECT-type E3 ligase regulating immunity, skin and cancer, Cell Death & Differentiation 2008 15:7 15 (2008) 1103–1112. https://doi.org/10.1038/cdd.2008.60. · DOI
  128. McGill, 2003, Mammalian Numb Proteins Promote Notch1 Receptor Ubiquitination and Degradation of the Notch1 Intracellular Domain, J. Biol. Chem., 278, 23196, 10.1074/jbc.M302827200 · DOI
  129. Shao, 2015, Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner, Mol Cancer, 14, 1, 10.1186/s12943-015-0295-3 · DOI
  130. Wang, 2010, The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness, Curr Drug Targets, 11, 745, 10.2174/138945010791170860 · DOI
  131. Tang, 2024, Current insights and future perspectives of ultraviolet radiation (UV) exposure: Friends and foes to the skin and beyond the skin, Environ Int, 185, 10.1016/j.envint.2024.108535 · DOI
  132. Bodine, 2014, Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1, Am J Physiol Endocrinol Metab, 307, 10.1152/ajpendo.00204.2014 · DOI
  133. Polge, 2018, A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate, J Cachexia Sarcopenia Muscle, 9, 10.1002/jcsm.12249 · DOI
  134. Peris-Moreno, 2021, UBE2L3, a Partner of MuRF1/TRIM63, Is Involved in the Degradation of Myofibrillar Actin and Myosin, Cells, 10, 10.3390/cells10081974 · DOI
  135. Latiano, 2013, Su1768 Genetic Risk Profiling of Complicated Disease Course in Crohn’s Disease Patients, Gastroenterology, 144, 10.1016/S0016-5085(13)61745-X · DOI
  136. Zhu, 2017, UBE2L3, ANCA, ASCA, and CBIR1 are Associated with Mechanisms of non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels, Gastroenterology, 152, 10.1016/S0016-5085(17)31514-7 · DOI
  137. Fransen, 2010, Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn’s disease, Hum Mol Genet, 19, 10.1093/hmg/ddq264 · DOI
  138. Peris-Moreno, 2021, Ube2l3, a partner of murf1/trim63, is involved in the degradation of myofibrillar actin and myosin, Cells, 10, 1974, 10.3390/cells10081974 · DOI
  139. Bawa, 2021, Trim32: A multifunctional protein involved in muscle homeostasis, glucose metabolism, and tumorigenesis, Biomolecules, 11, 10.3390/biom11030408 · DOI
  140. Locke, 2009, TRIM32 is an E3 ubiquitin ligase for dysbindin, Hum Mol Genet, 18, 10.1093/hmg/ddp167 · DOI
  141. Nicklas, 2012, TRIM32 regulates skeletal muscle stem cell differentiation and is necessary for normal adult muscle regeneration, PLoS One, 7, 10.1371/journal.pone.0030445 · DOI
  142. Kudryashova, 2005, Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin, J Mol Biol, 354, 10.1016/j.jmb.2005.09.068 · DOI
  143. S.C. Bodine, E. Latres, S. Baumhueter, V.K.M. Lai, L. Nunez, B.A. Clarke, W.T. Poueymirou, F.J. Panaro, Erqian Na, K. Dharmarajan, Z.Q. Pan, D.M. Valenzuela, T.M. Dechiara, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Identification of ubiquitin ligases required for skeletal Muscle Atrophy, Science (1979) 294 (2001). https://doi.org/10.1126/science.1065874. · DOI · Paper page
  144. Li, 2023, PINK1/Parkin-mediated mitophagy in neurodegenerative diseases, Ageing Res Rev, 84, 10.1016/j.arr.2022.101817 · DOI
  145. LeBlanc, 2021, Targeted modulation of E3 ligases using engineered ubiquitin variants, FEBS J, 288, 2143, 10.1111/febs.15536 · DOI
  146. Quinn, 2020, PINK1/PARKIN signalling in neurodegeneration and neuroinflammation, Acta Neuropathol Commun, 8, 10.1186/s40478-020-01062-w · DOI
  147. Tanji, 2010, TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson’s disease and dementia with Lewy bodies, Neurobiol Dis, 38, 10.1016/j.nbd.2010.01.007 · DOI
  148. Plooster, 2017, TRIM9-dependent ubiquitination of DCC constrains kinase signaling, exocytosis, and axon branching, Mol Biol Cell, 28, 10.1091/mbc.e16-08-0594 · DOI
  149. Menon, 2021, The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis, Mol Biol Cell, 32, 10.1091/mbc.E20-10-0622 · DOI · Paper page
  150. Harterink, 2019, Trim46 organizes microtubule fasciculation in the axon initial segment, J. Neurosci., 39, 10.1523/JNEUROSCI.3105-18.2019 · DOI
  151. Curcio, 2015, Microtubule Organization in the Axon: TRIM46 Determines the Orientation, Neuron, 88, 10.1016/j.neuron.2015.12.006 · DOI
  152. Ichinose, 2019, The Spatiotemporal Construction of the Axon Initial Segment via KIF3/KAP3/TRIM46 Transport under MARK2 Signaling, Cell Rep, 28, 10.1016/j.celrep.2019.07.093 · DOI
  153. Jiang, 2020, Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-kB Signaling through Ubiquitination of PPARa, Oncol Res, 28, 10.3727/096504020X15868639303417 · DOI
  154. Augustin, 2023, Targeting Cbl-b in cancer immunotherapy, J Immunother Cancer, 11, 10.1136/jitc-2022-006007 · DOI
  155. Boerth, 2023, Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity, ACS Med Chem Lett, 14, 10.1021/acsmedchemlett.3c00439 · DOI
  156. Thien, 1998, c-Cbl: A regulator of T cell receptor-mediated signalling, Immunol Cell Biol, 10.1046/j.1440-1711.1998.00768.x · DOI
  157. Nath, 2024, Mechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions, Life, 14, 1592, 10.3390/life14121592 · DOI
  158. Fang, 2001, Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells, Nat Immunol, 2, 870, 10.1038/ni0901-870 · DOI
  159. Gruber, 2013, Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells, J Mol Cell Biol, 5, 358, 10.1093/jmcb/mjt017 · DOI
  160. Venuprasad, 2010, Cbl-b and Itch: Key regulators of peripheral T cell tolerance, Cancer Res, 70, 3009, 10.1158/0008-5472.CAN-09-4076 · DOI
  161. Quinn, 2024, Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug Design, J Med Chem, 67, 14210, 10.1021/acs.jmedchem.4c01034 · DOI
  162. Li, 2023, Multiple Roles of TRIM21 in Virus Infection, Int J Mol Sci, 24
  163. Bourgeois-Daigneault, 2013, Tollip-induced down-regulation of MARCH1, Results Immunol, 3, 10.1016/j.rinim.2013.02.002 · DOI
  164. Madhukar, 2023, Current and Potential Pharmacological Targets for Therapeutic Intervention in Head and Neck Squamous Cell Carcinoma, Socio-Scientific Interaction in Diabetes and Cancer and Its Management
  165. Madhukar, 2020, Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma, Curr Cancer Drug Targets, 20
  166. Wang, 2020, RBR E3 ubiquitin ligases in tumorigenesis, Semin Cancer Biol, 67, 10.1016/j.semcancer.2020.05.002 · DOI
  167. Zhang, 2007, The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers, Nat Med, 13, 10.1038/nm1621 · DOI
  168. Cao, 2023, Expression and regulatory network of E3 ubiquitin ligase NEDD4 family in cancers, BMC Cancer, 23, 10.1186/s12885-023-11007-w · DOI
  169. Wang, 2017, E3 ubiquitin ligases in cancer and implications for therapies, Cancer Metastasis Rev., 36, 683, 10.1007/s10555-017-9703-z · DOI
  170. Mennerich, 2019, Dubs, hypoxia, and cancer, Trends Cancer, 5, 632, 10.1016/j.trecan.2019.08.005 · DOI
  171. Madhukar, 2021, Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma, Curr Cancer Drug Targets, 21, 386, 10.2174/1568009620666201229120332 · DOI
  172. Hanahan, 2011, Hallmarks of Cancer: The Next Generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  173. Liu, 2023, Expanding PROTACtable genome universe of E3 ligases, Nat Commun, 14, 6509, 10.1038/s41467-023-42233-2 · DOI
  174. Li, 2021, Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma, J. Exp. Clin. Cancer Res., 40, 10.1186/s13046-021-02026-1 · DOI
  175. Sciot, 2021, Mdm2 amplified sarcomas: A literature review, Diagnostics, 11, 10.3390/diagnostics11030496 · DOI
  176. Gao, 2021, Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2, Dokl Biochem Biophys, 500, 10.1134/S1607672921050070 · DOI
  177. Shi, 2012, Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity, Genes Cancer, 3, 240, 10.1177/1947601912455199 · DOI
  178. Zhu, 2022, Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials, J Hematol Oncol, 15, 10.1186/s13045-022-01314-3 · DOI · Paper page
  179. Mascarenhas, 2022, The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study, Blood Adv, 6, 1162, 10.1182/bloodadvances.2021006043 · DOI
  180. Khurana, 2019, MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388), Onco Targets Ther, 12, 2903, 10.2147/OTT.S172315 · DOI
  181. Deng, 2023, Correction: Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA viaRNA acetylation tofacilitate gastric cancer progression, J Exp Clin Cancer Res., 42, 9, 10.1186/s13046-022-02586-w · DOI
  182. Takahashi, 2021, Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, Japanese patients with solid tumors: A phase I study, Cancer Sci, 112, 2361, 10.1111/cas.14875 · DOI
  183. Gounder, 2023, A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas, Journal of Clinical Oncology, 41, 1714
  184. Nimmagadda, 2023, Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML), Blood, 142, 2782, 10.1182/blood-2023-174895 · DOI
  185. Wang, 2024, MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future, Pharmacol Rev, 76, 414
  186. Wang, 2010, Abstract 5373: Modulation of temozolomide-mediated DNA damage in glioblastoma multiforme by the HDM2 antagonist, nutlin3, Cancer Res, 70
  187. Lehman, 2013, Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes, PLoS One, 8, 10.1371/journal.pone.0074741 · DOI
  188. Saleh, 2021, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53, Clin. Cancer Res., 27, 5236, 10.1158/1078-0432.CCR-21-0715 · DOI · Paper page
  189. S. -Bayona, J.L. On, S. Ghaderi, C. Rittmann, G. Hoffmann, F. Gier, V. Woloschin, J.-W. Tu, S. Bhatia, A. Kulik, D. Niederacher, H. Neubauer, T. Kurz, T. Fehm, K. Esser, Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer, International Journal of Molecular Sciences 2025, Vol. 26, Page 1078 26 (2025) 1078. https://doi.org/10.3390/IJMS26031078. · DOI
  190. Gooding, 2021, Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma, Blood, 137, 10.1182/blood.2020007081 · DOI · Paper page
  191. Chrisochoidou, 2023, Investigating the functional impact of CRBN mutations on response to IMiD/Celmod Agents in Myeloma, Blood, 142, 10.1182/blood-2023-179986 · DOI
  192. Borsi, 2023, High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients, Clin Exp Med, 23, 10.1007/s10238-023-01205-y · DOI
  193. Ito, 2024, Protein degraders - from thalidomide to new PROTACs, J Biochem, 175, 10.1093/jb/mvad113 · DOI
  194. Zhang, 2023, Pan-cancer analysis reveals the prognostic and immunologic roles of cereblon and its significance for PROTAC design, Heliyon, 9
  195. Lopez-Girona, 2019, CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML), Blood, 134, 10.1182/blood-2019-127892 · DOI
  196. Fuchs, 2023, Targeting cereblon in hematologic malignancies, Blood Rev, 57, 10.1016/j.blre.2022.100994 · DOI · Paper page
  197. Surka, 2021, CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells, Blood, 137, 10.1182/blood.2020008676 · DOI · Paper page
  198. Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat Rev Cancer, 15, 10.1038/nrc3844 · DOI
  199. Stransky, 2022, Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway, Proc Natl Acad Sci U S A, 119, 10.1073/pnas.2120403119 · DOI
  200. Pilz, 2024, VHL-dependence of EHHADH Expression in a Human Renal Cell Carcinoma Cell Line, J Kidney Cancer VHL, 11

200 of 304 shown

Cited by

Sorted by citations

See all 26

Metadata

Authors
Madhukar, G., Haque, M. A., Khan, S., Kim, J.-J., & Danishuddin
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2025-06
Volume
236
Pages
116875
ISSN
0006-2952
DOI
10.1016/j.bcp.2025.116875
Cited by
26
References
13
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: E3 ubiquitin ligases and their therapeutic potential in disease Management. https://app.cochat.ai/papers/10.1016/j.bcp.2025.116875
The paper
Madhukar, G., Haque, M. A., Khan, S., Kim, J.-J., & Danishuddin. (2025). E3 ubiquitin ligases and their therapeutic potential in disease Management. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2025.116875